We are a clinical-stage biotechnology company developing best-in-class bromodomain and extra-terminal inhibitors (BETi) for the treatment of multiple cancers and other disorders with significant unmet medical need. Our goal is to be a leading oncology company in the field of epigenetics, translating bromodomain biology into impactful, targeted therapeutics for the benefit of patients.

Learn More

About Zenith Epigenetics

Zenith Epigenetics’ experienced research team has developed a cutting-edge epigenetic platform, generating differentiated, potent, and selective BET inhibitors. Our experienced management team and world-leading clinical collaborators are developing BETi combination therapies for multiple oncology indications. With a strong emphasis on translational medicine – for selecting patients that will benefit most from the therapy – Zenith is a leader in innovative clinical development of epigenetic combination therapies.

Our lead BETi, ZEN-3694, is in Phase 2 clinical development for the treatment of prostate cancer and breast cancer, the latter in collaboration with Pfizer.



Epigenetic Therapeutic Targets

On July 15, 2021, Zenith presented at the Epigenetic Therapeutic Targets digital event

"Clinical Development of The BET Bromodomain Inhibitor ZEN-3694 In Solid Tumors: Lessons Learned"
• Design of epigenetic combinatorial therapies
• Clinical activity in breast and prostate cancer patients
• Mechanisms of action: similarities and differences between the prostate
and breast cancer trials

Read More Add This to my Calendar

OICR Jlabs Cancer Symposium

On June 1, 2021, Zenith presented at the OICR Jlabs Cancer Symposium with regards to the clinical development of the BET bromodomain inhibitor ZEN-3694 in multiple oncology indications.

Read More Add This to my Calendar

Triple Negative Breast Cancer Drug Development Digital Summit 2021

On April 29, 2021, Zenith Epigenetics presented at the Triple Negative Breast Cancer Drug Development Digital Summit 2021, the following: "Phase 1b/2 Combination Study of the BET Inhibitor ZEN-3694 with the PARP Inhibitor Talazoparib for the Treatment of TNBC Patients without gBRCA1/2 Mutations." 

Read More Add This to my Calendar

AACR Annual Meeting 2021 - Virtual

On April 10, 2021, Zenith Epigenetics presented at the AACR Annual Meeting 2021 - Virtual, the following poster: "Combination of ZEN-3694 with talazoparib is a novel therapeutic approach in ER positive breast cancer resistant to CDK4/6 inhibitors, independent of BRCA status." 

Read More Add This to my Calendar